Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial

David T. Yeung, BSc, MBBS, FRACP, FRCPA, Michael Osborn, MBBS, FRACP, FRCPA, Deborah L. White, PhD. FFSc(RCPA), Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, FRACP, FRCPA, Devendra K Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, FRACP, FRCPA

Blood (2011) 118 (21): 451.

https://doi.org/10.1182/blood.V118.21.451.451

Published: 2011

Journal Articles

The Strategy of Early Nilotinib Switch Based on Failure to Achieve Optimal Molecular Targets on Imatinib May Not Overcome the Negative Impact of a Low OCT-1 Activity in De-Novo CP-CML Patients

Deborah L. White, PhD. FFSc(RCPA), Verity A Saunders, BScHons, Amity Frede, BScHons, Kelvin GrootObbink, BScHons, Cassandra Slader, PhD, David T. Yeung, BSc, MBBS, FRACP, FRCPA, Michael Osborn, MBBS, FRACP, FRCPA, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P Hughes, MD, MBBS

Blood (2011) 118 (21): 1690.

https://doi.org/10.1182/blood.V118.21.1690.1690

Published: 2011

Journal Articles

Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial

David T. Yeung, MBBS, Michael Osborn, MBBS, FRACP, FRCPA, Deborah L. White, PhD, Susan Branford, PhD, Lauren Haswell, MSci, Cassandra Slader, PhD, Samar Issa, FRACP, FRCPA, Devendra K. Hiwase, MBBS, PhD, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K. Arthur, MBBS, Yiu Lam Kwan, MBBS, FRACP, FRCPA, Cecily J. Forsyth, FRACP, FRCPA, David M. Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS, on Behalf Of ALLG

Blood (2010) 116 (21): 209.

https://doi.org/10.1182/blood.V116.21.209.209

Published: 2010

Journal Articles

Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study

Deborah L. White, PhD, Verity Saunders, Amity Frede, Kelvin GrootObbink, Cassandra Slader, PhD, David T. Yeung, MBBS, Michael Osborn, MBBS, FRACP, FRCPA, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS

Blood (2010) 116 (21): 356.

https://doi.org/10.1182/blood.V116.21.356.356

Published: 2010

Journal Articles

Ethylene Diamine Tetra Acetic Acid (EDTA) Decalcification of Paediatric Bone Marrow Trephines In a Diagnostic Laboratory

Shriram Vaidia Nath, FRCPA, DM, MD, D.Ped, MBBS, Michelle Tamblyn, Dip., Med., Tech, Grad, Cert, Surg, Path, Prep, Susan Telfer, BSc(Hons), Grad, Cert, Surg, Path, Prep, Tony Henwood, JP, MSc, BAppSc, GradDipSysAnalys, CT(ASC), Peter Gilham, Colin Story, MSc, Greg Hodge, PhD, Akash Kalro, FRCPA, Michael Osborn, MBBS, FRACP, FRCPA, Ram Suppiah, MBBS, FRACP, FRCPA, Heather Tapp, MBBS, FRACP, FRCPA, Ian C Nicholson, PhD, BSc(Hons), BSc, Heddy Zola, PhD, FRCPA, Sarah Moore, B, App, Sci, BSc(Hons), Andrew Zannettino, BSc, PhD, Nick Manton, FRCPA, Tamas Revesz, MD, PhD, FRACP

Blood (2010) 116 (21): 2566.

https://doi.org/10.1182/blood.V116.21.2566.2566

Published: 2010

Journal Articles

Imatinib PK: Observations From the TIDEL II Study

Deborah L. White, PhD, Verity Saunders, Menelaou Andrew, Allan Rofe, PhD, Cassandra Slader, PhD, David T. Yeung, MBBS, Michael Osborn, MBBS, FRACP, FRCPA, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS

Blood (2010) 116 (21): 2288.

https://doi.org/10.1182/blood.V116.21.2288.2288

Published: 2010

NARROW

Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial

The Strategy of Early Nilotinib Switch Based on Failure to Achieve Optimal Molecular Targets on Imatinib May Not Overcome the Negative Impact of a Low OCT-1 Activity in De-Novo CP-CML Patients

Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial

Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study

Ethylene Diamine Tetra Acetic Acid (EDTA) Decalcification of Paediatric Bone Marrow Trephines In a Diagnostic Laboratory

Imatinib PK: Observations From the TIDEL II Study

Email alerts

ASH Publications

American Society of Hematology

Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial

The Strategy of Early Nilotinib Switch Based on Failure to Achieve Optimal Molecular Targets on Imatinib May Not Overcome the Negative Impact of a Low OCT-1 Activity in De-Novo CP-CML Patients

Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial

Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study

Ethylene Diamine Tetra Acetic Acid (EDTA) Decalcification of Paediatric Bone Marrow Trephines In a Diagnostic Laboratory

Imatinib PK: Observations From the TIDEL II Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only